The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZYME | +8.54% | -55.85% | -15.08% | +39% |
| S&P | +13.96% | +91.24% | +13.85% | +187% |
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab’s unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
The biotech stock's shares may have been pushed by a short squeeze.
Investors applauded a major licensing deal with Jazz Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $27.61M | 72.6% |
| Gross Profit | $25.03M | 87.7% |
| Gross Margin | 90.64% | 7.3% |
| Market Cap | $1.29B | 43.9% |
| Market Cap / Employee | $4.92M | 60.9% |
| Employees | 263 | -10.5% |
| Net Income | -$19.60M | 34.3% |
| EBITDA | -$19.53M | 38.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $64.83M | -47.0% |
| Accounts Receivable | $29.35M | 23.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.50M | -10.4% |
| Short Term Debt | $3.40M | 15.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.34% | 7.4% |
| Return On Invested Capital | -30.80% | 4.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$32.33M | -359.1% |
| Operating Free Cash Flow | -$31.92M | -419.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.80 | 2.44 | 2.71 | 3.85 | 74.54% |
| Price to Sales | 14.32 | 9.59 | 7.90 | 9.62 | -37.35% |
| Price to Tangible Book Value | 2.95 | 2.57 | 2.84 | 4.02 | 73.46% |
| Enterprise Value to EBITDA | -47.81 | -29.10 | 278.90 | -54.34 | 152.64% |
| Return on Equity | -30.5% | -29.8% | -19.9% | -18.5% | -35.73% |
| Total Debt | $18.51M | $18.46M | $18.68M | $18.90M | -6.65% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
